N-acetylcysteine Pharmacology and Applications in Rare Diseases-Repurposing an Old Antioxidant.
Level 5 - mechanism / opinion, no new human data
Narrative review of pharmacology and preclinical/clinical literature without systematic review methodology
PubMed 37507857 · doi:10.3390/antiox12071316
What was done
This narrative review synthesized literature on N-acetylcysteine (NAC) pharmacology, history of clinical use, safety, pharmacokinetics, and antioxidant mechanisms as a glutathione precursor. The authors evaluated literature regarding the exploration and repurposing of NAC and its structural derivatives for rare diseases targeting mitochondrial dysfunction.
What was found
The abstract reports no quantitative outcome numbers, statistical values, or effect sizes. It notes that systematic clinical pharmacology data—specifically pharmacokinetics, pharmacodynamic targets, drug interactions, and dose-ranging—remain severely limited, and clinical evidence for rare disease indications consists largely of anecdotal reports and early-stage studies.
Why it matters
It maps the therapeutic potential and mechanistic rationale for repurposing NAC in rare diseases involving mitochondrial dysfunction while emphasizing the substantial research gaps in dosing and pharmacology.
Limits
The paper is a non-systematic narrative review with no new human data. The evidence base discussed relies heavily on anecdotal reports, mechanistic reasoning, and preclinical studies, with an absence of formal dose-ranging and pharmacokinetic/pharmacodynamic trial data.
Cited by
- context N-acetylcysteine (NAC) functions as an antioxidant and recycles the glutathione peroxidase system to mitigate oxidative stress.